한빛사논문
- 조회1,420
Soon Gang Choi1,2,3,14, Julien Olivet1,2,3,4,14, Patricia Cassonnet5,14, Pierre-Olivier Vidalain6,14, Katja Luck1,2,3, Luke Lambourne1,2,3, Kerstin Spirohn1,2,3, Irma Lemmens7,8, Mélanie Dos Santos5, Caroline Demeret5, Louis Jones9, Sudharshan Rangarajan1,2,3, Wenting Bian1,2,3, Eloi P. Coutant10, Yves L. Janin10, Sylvie van der Werf5, Philipp Trepte11,12, Erich E. Wanker11, Javier De Las Rivas13, Jan Tavernier7,8, Jean-Claude Twizere4, Tong Hao1,2,3, David E. Hill1,2,3, Marc Vidal1,2,*, Michael A. Calderwood1,2,3,* & Yves Jacob1,5,*
1 Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute (DFCI), 450 Brookline Avenue, Boston, MA 02215, USA.
2 Department of Genetics, Blavatnik Institute, Harvard Medical School (HMS), 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
3 Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
4 Laboratory of Viral Interactomes, Unit of Molecular Biology of Diseases, Groupe Interdisciplinaire deGénomique Appliquée (GIGA Institute), University of Liège, 7 Place du 20 Août, 4000 Liège, Belgium.
5 Département de Virologie, Unité de Génétique Moléculaire des Virus à ARN (GMVR), Institut Pasteur, UMR3569, Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot, Sorbonne Paris Cité, 28 rue du Docteur Roux, 75015 Paris, France.
6 Équipe Chimie, Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques (LCBPT), Centre Interdisciplinaire Chimie Biologie-Paris (CICB-Paris), UMR8601, CNRS, Université Paris Descartes, 45 rue des Saints-Pères, 75006 Paris, France.
7 Center for Medical Biotechnology, Vlaams Instituut voor Biotechnologie (VIB), 3 Albert Baertsoenkaai, 9000 Ghent, Belgium.
8 Cytokine Receptor Laboratory (CRL), Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, 3Albert Baertsoenkaai, 9000 Ghent, Belgium.
9 Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), Institut Pasteur, 28 rue du Docteur Roux, 75015 Paris, France.
10 Département de Biologie Structurale et Chimie, Unité de Chimie et Biocatalyse, Institut Pasteur, UMR3523, CNRS, 28 rue du Docteur Roux, 75015 Paris, France.
11 Neuroproteomics, Max Delbrück Center for Molecular Medicine, 10 Robert-Rössle-Str., 13125 Berlin, Germany.
12 Brain Development and Disease, Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), 3 Dr. Bohr-Gasse, 1030 Vienna, Austria.
13 Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca (USAL), Campus Miguel de Unamuno, 37007 Salamanca, Spain.
14 These authors contributed equally: Soon Gang Choi, Julien Olivet, Patricia Cassonnet, Pierre-Olivier Vidalain
*Correspondence to Marc Vidal or Michael A. Calderwood or Yves Jacob
Abstract
Complementary assays are required to comprehensively map complex biological entities such as genomes, proteomes and interactome networks. However, how various assays can be optimally combined to approach completeness while maintaining high precision often remains unclear. Here, we propose a framework for binary protein-protein interaction (PPI) mapping based on optimally combining assays and/or assay versions to maximize detection of true positive interactions, while avoiding detection of random protein pairs. We have engineered a novel NanoLuc two-hybrid (N2H) system that integrates 12 different versions, differing by protein expression systems and tagging configurations. The resulting union of N2H versions recovers as many PPIs as 10 distinct assays combined. Thus, to further improve PPI mapping, developing alternative versions of existing assays might be as productive as designing completely new assays. Our findings should be applicable to systematic mapping of other biological landscapes.
논문정보
- Research article
- 2019년 08월 (BRIC 등록일 2019-09-19)
- 국외 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
